Navigation Links
Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
Date:7/23/2008

issued in connection with the $17.5 million of notes are also being surrendered to the Company and will be cancelled.

The new Notes have a $44.5 million initial principal balance and feature a make-whole provision entitling the holder, upon any conversion of the Notes, to receive the interest payable through scheduled maturity, less any interest paid before conversion. The Company expects to receive net proceeds of approximately $21.8 million from the portion of the notes funded this week, prior to depositing amounts in escrow for the make-whole provision and the repurchase of prior notes and warrants as described above, and a similar amount prior to August 25, 2008. The Notes will rank equal in right of payment with all existing and future unsecured senior indebtedness of the Company. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.

This press-release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the investor might, if it breaches its agreement, not fund the remaining $22.25 million prior to August 25, 2008; the investor may choose not to purchase any of the additional warrant securities for $44.5 million or at all; the Company may not receive the necessary approvals to sell such additional securities on these terms; these transactions will be highly dilutive to our current stockholders; the Company continues to have a substantial amount of debt outstanding and the quarterly interest expense associated with the debt is significant; the Company's operating expenses continue
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
2. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
3. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
5. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
6. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
7. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
9. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
10. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
11. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... NASHVILLE, Tenn. , July 6, 2015 ... has entered into a definitive agreement to ... technology and intervention platforms that combine data ... and reporting capabilities to achieve actionable insights ... acquisition will combine Altegra Health,s risk adjustment ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
(Date:7/3/2015)... ... 03, 2015 , ... The global failure analysis market is expected to reach ... bioscience market is expected to grow at the highest CAGR of 8.46%; its growth ... the research labs and academic institutions for root cause analysis of failure. The market ...
(Date:7/2/2015)... Brooklyn, NY (PRWEB) , ... July 03, 2015 , ... Cuvettes have been used in ... book style catalog to find the cuvette they needed. As expected, this was a ... would order the wrong part because they were not able to navigate the complex catalog ...
Breaking Biology Technology:Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2
... Processing, Industry,VANCOUVER, March 2 /PRNewswire-FirstCall/ ... Company") today announced that it has completed the ... equipment to CAL-SAN Enterprises, Ltd. of Richmond, B.C. ... this sale, EnWave has proven that it can ...
... invivodata, inc., ( http://www.invivodata.com ... reported outcomes (ePRO) solutions and services for ... of featured presentations at upcoming international events ... and its scientific and regulatory consulting division, ...
... Inc., a subsidiary of,Eisai Corporation of North America, ... II study of its MORAb-009 monoclonal antibody in,mesothelioma. ... drugs,pemetrexed and cisplatinum, as a first-line treatment for ... primary objective of the study is to assess ...
Cached Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4invivodata and PRO Consulting to Present at International Industry Events 2invivodata and PRO Consulting to Present at International Industry Events 3Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Sharp has selected its industry-leading Natural ... its latest flagship smartphone device, the AQUOS ZETA ... shipments of its fingerprint ID sensor technology, this ... and leadership in the biometrics market through its ...
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... SANTA CRUZ, CA--Researchers at the University of California, Santa Cruz, ... migrations of elephant seals have compiled one of the largest ... and diving behavior at sea in unprecedented detail. ... PLoS ONE focuses on the annual migrations of adult ...
... saliva of the Gila monster lizard is effective in ... Academy, University of Gothenburg, have tested the drug on ... food and chocolate. An increasing number of patients ... preparation called Exenatide, which helps them to control their ...
... have now been found in shipwrecks both in the Baltic ... the results, presented in the Journal of Archaeological Science, ... University. A few years ago scientists reported large quantities ... warship Vasa, resulting in the development of sulphuric acid ...
Cached Biology News:Elephant seal tracking reveals hidden lives of deep-diving animals 2Elephant seal tracking reveals hidden lives of deep-diving animals 3Drugs from lizard saliva reduces the cravings for food 2Sulphur and iron compounds common in old shipwrecks 2
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: